Effective control of rush progression of CD8+ mycosis fungoides with pegylated interferon.
Fujimura
Taku
T
Okuyama
Ryuhei
R
Hashimoto
Akira
A
Watanabe
Hiroshi
H
Nakagawa
Satoshi
S
Tagami
Hachiro
H
Aiba
Setsuya
S
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018414:CD8-Positive T-Lymphocytes / Q000473:pathology; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D009182:Mycosis Fungoides / Q000276:immunology / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011882:Radiotherapy, High-Energy; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a